AstraZeneca immune system drug wins orphan status in rare cancer

April 15, 2015 6:00 AM

1 0

LONDON, April 15 (Reuters) - An experimental medicine from AstraZeneca that helps the immune system fight tumours has won "orphan" drug status in the United States for treating malignant mesothelioma, a rare type of cancer.

Tremelimumab is one of a number of immuno-oncology products that AstraZeneca is banking on as it focuses heavily on promising new treatments for cancer.

Read more

To category page